Form 4: Gilead Sciences' Chief Medical Officer Merdad Parsey Sells 2,000 Shares
SEC Form 4
Gilead Sciences' Chief Medical Officer, Merdad Parsey, sold 2,000 shares of common stock on April 1, 2024, at a price of $72.96 per share, according to a Form 4 filing with the SEC.
Summary
- On April 1, 2024, Merdad Parsey, the Chief Medical Officer of Gilead Sciences, sold 2,000 shares of Gilead Sciences' common stock.
- The sale was executed at a price of $72.96 per share.
- Following the transaction, Parsey directly owns 96,304 shares of Gilead Sciences' common stock.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 9, 2023.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.
Stakeholder Impact
- The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2023-11-09 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-04-01 | Date of stock sale transaction |
| 2024-04-02 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.